Epibone Our eb iac product is an allogenic, injectable cartilage product for treating low grade cartilage lesions that don't involve underlying bone. stem cells from a cell bank are processed into condensed mesenchymal cells primed for cartilage formation. Using proven science and engineering, epibone is working to help people live happier and more active lives. skeletal conditions are the #1 cause of disability worldwide, and yet still are mostly treated with a mix of pain meds and carpentry.
Epibone About press copyright contact us creators advertise developers terms privacy policy & safety how works test new features nfl sunday ticket © 2025 google llc. Sitting at the intersection of biology and engineering, the company harnesses the power of cells to create living solutions that can become a seamless part of a patient’s body. epibone is currently developing a pipeline of bone, cartilage, and compound (bone and cartilage) products. Clinical trials will evaluate the safety and efficacy of epibone's graft compared to current treatment, with patient recruitment set to begin as soon as early 2024. epibone has received. Epibone is a biotech company that provides bone reconstruction solutions.
Epibone Clinical trials will evaluate the safety and efficacy of epibone's graft compared to current treatment, with patient recruitment set to begin as soon as early 2024. epibone has received. Epibone is a biotech company that provides bone reconstruction solutions. Epibone is transforming skeletal repair through groundbreaking regenerative technology, using stem cells to create living bone and cartilage implants that address the root causes of trauma and degenerative conditions. Epibone’s injectable cellular cartilage repair product,eb iac (product trailer), and osteo chondral graft,eb oc (product trailer), solve the supply constraints on living human tissue grafts for joint repair. Clinical trials will evaluate the safety and efficacy of epibone’s graft compared to current treatment, with patient recruitment set to begin as soon as early 2024. Clinical trials will evaluate the safety and efficacy of epibone’s graft compared to current treatment, with patient recruitment set to begin as soon as early 2024.
Comments are closed.